祝贺：时晓庆老师和丁佳戈老师 

    恭喜您们在学术道路上又取得了新的成就！您们的文献发表是对多年来不懈追求学术进步的最好证明，更是您们所掌握知识的体现，祝愿您在未来的学术道路上继续勇往直前，创造更多辉煌的成就！
        

        时小庆感言：未来之路，需要不断努力，既然选择了医学，就要坚持自己的使命。

        丁佳戈感言：不管遇到什么困难，只要坚持去做，就会越来越好，离成功也就越来越近

        柴大飞导师寄语：自信，自立，自强，去追逐梦想，实现人生价值。

        HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

        简介：Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8+T cells and DCs. Furthermore, the PLGA/PEI-HMGB1/GPC3 vaccine induced a strong CTL effect and promoted functional CD8+T cell proliferation. Intriguingly, the depletion assay proved that the therapeutic effect PLGA/PEI-HMGB1/GPC3 vaccine was dependent on antigen-specific CD8+T cell immune responses. In the rechallenge experiment, PLGA/PEI-HMGB1/GPC3 vaccine provided a long-lasting resistance to the growth of the contralateral tumor by inducing the memory CD8+T cell responses. Collectively, PLGA/PEI-HMGB1/GPC3 vaccine could induce a strong and long-lasting CTL effect and inhibit the tumor progression or re-attack. Therefore, the combined co-immunization of PLGA/PEI-HMGB1/GPC3 might be served as an effective anti-tumor strategy against HCC.